Ian Neeland, MD
- Clinical Assistant Professor, CWRU School of Medicine
Ian J. Neeland, MD, is director of cardiovascular prevention and co-director of the Center for Integrated and Novel Approaches in Vascular-Metabolic Disease for University Hospitals Harrington Heart & Vascular Institute. He is also an associate professor of medicine at Case Western Reserve University School of Medicine. He is a general cardiologist with special expertise in obesity, diabetes and cardiovascular disease.
Dr. Neeland earned his medical degree at Mount Sinai School of Medicine in New York City. He completed a residency in internal medicine and was chief medical resident at Emory University School of Medicine in Atlanta, and then completed a combined clinical and research fellowship in cardiovascular medicine at UT Southwestern Medical Center in Dallas. He also holds a certificate in translational medicine from Emory's Laney Graduate School. Certified by the American Board of Internal Medicine in both internal medicine and cardiovascular diseases, he also holds a subspecialty certification in adult echocardiography from the National Board of Echocardiography.
Dr. Neeland is an active clinical and translational investigator with funding from the National Institutes of Health and industry. He has published over 80 scholarly articles and delivered a number of national, international and regionally invited lectures. He is a reviewer for many respected journals, including Circulation, for which he currently serves as an associate editor and section editor for Bridging Disciplines.
Dr. Neeland is a Fellow of the American Heart Association and serves on several national committees with the American Heart Association. Dr. Neeland is a member of professional organizations that include the AHA Council on Epidemiology and Prevention and the Council on Lifestyle and Cardiometabolic Health; American College of Cardiology; and American Society for Preventive Cardiology.
- Cardiovascular Diseases
- Diabetic Cardiology
- Preventive Cardiology
- Cardiovascular Disease - American Board of Internal Medicine
- Internal Medicine - American Board of Internal Medicine
Fellowship | Cardiovascular Disease
Cardiovascular Disease - University Of Texas Southwestern Medical Center (2011 - 2015)
Residency | Internal Medicine/Chief Resident
Internal Medicine/Chief Resident - Emory University Hospital (2010 - 2011)
Residency | Internal Medicine
Internal Medicine - Emory University Hospital (2007 - 2010)
Icahn School Of Medicine At Mount Sinai (2007)
University Of Pennsylvania (2002)
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Ian Neeland did not disclose any Outside Relationships with Industry.